Tag: 858 Therapeutics

858 Therapeutics has filed a notice of an exempt offering of securities to raise $50,350,497.00 in New Equity Investment.

858 Therapeutics has filed a notice of an exempt offering of securities to raise $50,350,497.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, 858 Therapeutics is raising up to $50,350,497.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Jeffrey Stafford…

Read More Read More